The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA
TX
247, and derivatives thereof. Mixtures of ISA
TX
247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISA
TX
247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture comprises greater than about 80 percent by weight of the E-isomer and less than about 20 percent by weight of the Z-isomer, based on the total weight of the mixture.
这项发明涉及与
环孢霉素A结构相似的
环孢霉素类似物的异构混合物。这些混合物具有比单个异构体以及自然存在和其他目前已知的
环孢霉素和
环孢霉素衍
生物具有增强的功效和降低毒性。本发明的实施例涉及被称为I
SATX247的
环孢霉素A类似物的顺式和反式异构体,以及其衍
生物。I
SATX247异构体的混合物表现出比自然存在和目前已知的
环孢霉素具有更强效和降低毒性的组合。I
SATX247异构体和烷基化、芳基化和
氘化衍
生物是通过立体选择性途径合成的,其中反应的特定条件决定了立体选择性的程度。混合物中异构体的比例包括E-异构体的重量大约超过80%,Z-异构体的重量小于混合物的总重量的20%。